Successful Completion of the Pilot Phase of a Randomized Controlled Trial Comparing Sentinel Lymph Node Biopsy to No Further Axillary Staging in Patients with Clinical T1-T2 N0 Breast Cancer and Normal Axillary Ultrasound

详细信息    查看全文

• 作者：Amy E. Cyr ; MD ; FACS^a ; ^{cyra@wudosis.wustl.edu" class="auth_mail" title="E-mail the corresponding author} ; Natalia Tucker ; MD^a ; Foluso Ademuyiwa ; MD^b ; Julie A. Margenthaler ; MD ; FACS^a ; Rebecca L. Aft ; MD ; FACS^a ; Timothy J. Eberlein ; MD ; FACS^a ; Catherine M. Appleton ; MD^c ; Imran Zoberi ; MD^d ; Maria A. Thomas ; MD ; PhD^d ; Feng Gao ; PhD^a ; ^e ; William E. Gillanders ; MD ; FACS^a
• 关键词：ALND ; axillary lymph node dissection ; AUS ; axillary ultrasound ; ER ; estrogen receptor ; HER ; human epidermal growth factor ; NPV ; negative predictive value ; PR ; progesterone receptor ; SLNB ; sentinel lymph node biopsy ; WUSM ; Washington University School of Medicine
• 刊名：Journal of the American College of Surgeons
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：223
• 期：2
• 页码：399-407
• 全文大小：458 K

文摘

Axillary surgery is not considered therapeutic in patients with clinical T1-T2 N0 breast cancer. The importance of axillary staging is eroding in an era in which tumor biology, as defined by biomarker and gene expression profile, is increasingly important in medical decision making. We hypothesized that axillary ultrasound (AUS) is a noninvasive alternative to sentinel lymph node biopsy (SLNB), and AUS could replace SLNB without compromising patient care.

Study Design

Patients with clinical T1-T2 N0 breast cancer and normal AUS were eligible for enrollment. Subjects were randomized to no further axillary staging (arm 1) vs SLNB (arm 2). Descriptive statistics were used to describe the results of the pilot phase of the randomized controlled trial.

Results

Sixty-eight subjects were enrolled in the pilot phase of the trial (34 subjects in arm 1, no further staging; 32 subjects in arm 2, SLNB; and 2 subjects voluntarily withdrew from the trial). The median age was 61 years (range 40 to 80 years) in arm 1 and 59 years (range 31 to 81 years) in arm 2, and there were no significant clinical or pathologic differences between the arms. Median follow-up was 17 months (range 1 to 32 months). The negative predictive value (NPV) of AUS for identification of clinically significant axillary disease (>2.0 mm) was 96.9%. No axillary recurrences have been observed in either arm.

Conclusions

Successful completion of the pilot phase of the randomized controlled trial confirms the feasibility of the study design, and provides prospective evidence supporting the ability of AUS to exclude clinically significant disease in the axilla. The results provide strong support for a phase 2 randomized controlled trial.